SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	106.01	16.27	15.85
Short-Term Investments	12.03	-	24.47
Cash & Cash Equivalents	118.04	16.27	40.32
Cash Growth	-	-59.65%	-
Receivables	0.42	0.42	0.12
Other Current Assets	1.24	0.72	0.18
Total Current Assets	119.7	17.41	40.61
Property, Plant & Equipment	-	2.17	0.45
Goodwill and Intangibles	-	3.29	-
Other Long-Term Assets	-	0.45	0.09
Total Long-Term Assets	-	5.91	0.53
Total Assets	-	23.32	41.15
Accounts Payable	-	1.98	0.64
Current Debt	-	3.86	-
Other Current Liabilities	6.61	1.95	0.95
Total Current Liabilities	6.61	7.79	1.59
Long-Term Debt	-	3.46	-
Total Long-Term Liabilities	-	3.46	0
Total Liabilities	-	11.25	1.59
Total Debt	3.57	7.31	0
Retained Earnings	-	-64.86	-35.7
Shareholders' Equity	-87.22	-60.47	-32.99
Net Cash (Debt)	114.47	8.95	40.32
Net Cash (Debt) Growth	-	-77.79%	-
Working Capital	113.09	9.61	39.03

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).